These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18999912)

  • 21. [Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood].
    Seror V; Moatti JP; Muller F; Le Galès C; Boué A
    Rev Epidemiol Sante Publique; 1993; 41(1):3-15. PubMed ID: 8465062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Amniocentesis practice assessment of the south-west Francilian network during 2003].
    Laperrelle J; Senat MV; Picone O; Fernandez H; Frydman R
    J Gynecol Obstet Biol Reprod (Paris); 2008 Apr; 37(2):135-42. PubMed ID: 18036746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of second trimester amniocentesis in twin pregnancies at Songklanagarind Hospital.
    Hanprasertpong T; Kor-anantakul O; Prasartwanakit V; Leetanaporn R; Suntharasaj T; Suwanrath C
    J Med Assoc Thai; 2008 Nov; 91(11):1639-43. PubMed ID: 19127782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in prenatal screening and diagnostic testing among women referred for advanced maternal age.
    Nakata N; Wang Y; Bhatt S
    Prenat Diagn; 2010 Mar; 30(3):198-206. PubMed ID: 20063323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete trisomy 21 vs translocation Down syndrome: a comparison of modes of ascertainment.
    Bornstein E; Lenchner E; Donnenfeld A; Jodicke C; Keeler SM; Kapp S; Divon MY
    Am J Obstet Gynecol; 2010 Oct; 203(4):391.e1-5. PubMed ID: 20691415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down syndrome: prenatal risk assessment and diagnosis.
    Newberger DS
    Am Fam Physician; 2000 Aug; 62(4):825-32, 837-8. PubMed ID: 10969860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prenatal diagnosis. Review, personal and prospective studies].
    Engel E; Empson J; DeLozier D; McGee B; da Costa Woodson E; Engel-de Montmollin M; Carter T; Lorber C; Cassidy SB; Millis J; Heller RM; Boehm F; Vanhooydonk J
    Schweiz Med Wochenschr; 1979 Jul; 109(27):998-1010. PubMed ID: 88763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [How to improve the screening and diagnosis of fetal aneuploidy?].
    Ville Y
    Bull Acad Natl Med; 2005 Nov; 189(8):1773-84; discussion 1784-7. PubMed ID: 16737102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of congenital anomalies at birth among offspring of women at risk for a genetic disorder and with a normal second-trimester ultrasound.
    Lemyre E; Infante-Rivard C; Dallaire L
    Teratology; 1999 Oct; 60(4):240-4. PubMed ID: 10508977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fetal loss after amniocentesis in a series of 5,780 procedures.
    Gaudry P; Grangé G; Lebbar A; Choiset A; Girard S; Goffinet F; Lewin F
    Fetal Diagn Ther; 2008; 23(3):217-21. PubMed ID: 18417981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Routine assessment of amniotic fluid alpha-Fetoprotein in early second-trimester amniocentesis is no longer justified.
    Widlund KF; Gottvall T
    Acta Obstet Gynecol Scand; 2007; 86(2):167-71. PubMed ID: 17364279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prenatal diagnosis of chromosome aberrations after implementation of screening for Down's syndrome].
    Kjaergaard S; Hahnemann JM; Skibsted L; Jensen LN; Sperling L; Zingenberg H; Kristiansen A; Brøndum-Nielsen K
    Ugeskr Laeger; 2008 Mar; 170(14):1152-6. PubMed ID: 18405480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-trimester Down syndrome screening in women younger than 35 years old and cost-effectiveness analysis in Taiwan population.
    Chou CY; Hsieh FJ; Cheong ML; Lee FK; She BQ; Tsai MS
    J Eval Clin Pract; 2009 Oct; 15(5):789-96. PubMed ID: 19811590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The prenatal detection of trisomy 13, 18, and 21: comparison of the advanced first trimester screening (AFS) with the first trimester screening according to Nicolaides].
    Hörmansdörfer C; Schmidt P; Hillemanns P; Scharf A
    Z Geburtshilfe Neonatol; 2007 Dec; 211(6):243-9. PubMed ID: 18176905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fetuses with Down's Syndrome detected by prenatal screening are more likely to abort spontaneously than fetuses with Down's Syndrome not detected by prenatal screening.
    Leporrier N; Herrou M; Morello R; Leymarie P
    BJOG; 2003 Jan; 110(1):18-21. PubMed ID: 12504930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fetal Down syndrome screening: a cost effectiveness analysis of alternative screening programs.
    Cusick W; Vintzileos AM
    J Matern Fetal Med; 1999; 8(6):243-8. PubMed ID: 10582856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-trimester genetic amniocentesis: 5-year experience.
    Turhan NO; Eren U; Seçkin NC
    Arch Gynecol Obstet; 2005 Jan; 271(1):19-21. PubMed ID: 15290165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maternal age-specific fetal loss rates in Down syndrome pregnancies.
    Savva GM; Morris JK; Mutton DE; Alberman E
    Prenat Diagn; 2006 Jun; 26(6):499-504. PubMed ID: 16634111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evaluation of the third trimester amniocentesis for fetal karyotyping in women with fear of pregnancy loss].
    Picone O; Fuchs F; Sénat MV; Brisset S; Tachdjian G; Audibert F; Fernandez H; Frydman R
    J Gynecol Obstet Biol Reprod (Paris); 2008 Jun; 37(4):385-91. PubMed ID: 18191913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.